Gabriel N. Hortobagyi, MD, on Early Breast Cancer: Final Invasive Disease–Free Analysis From the NATALEE Trial
2023 SABCS
Gabriel N. Hortobagyi, MD, of The University of Texas MD Anderson Cancer Center, discusses findings from the NATALEE trial, which continued to demonstrate improved invasive disease–free survival with ribociclib plus a nonsteroidal aromatase inhibitor (NSAI) over a NSAI alone in patients with hormone receptor–positive, HER2-negative early breast cancer (Abstract GS03-03).
The ASCO Post Staff
Sherene Loi, MD, PhD, of Australia’s Peter McCallum Cancer Centre, discusses an exploratory analysis of CheckMate 7FL which showed that patients with PD-L1–positive, high-risk, estrogen receptor–positive, HER2-negative primary breast cancer may achieve substantial pathologic complete response rates with the addition of nivolumab to neoadjuvant chemotherapy (Abstract GS01-01).
The ASCO Post Staff
Peter Schmid, MD, PhD, of Queen Mary University of London and Barts Cancer Institute, discusses phase III findings from KEYNOTE-522 showing that neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab continues to show a clinically meaningful improvement in event-free survival compared with neoadjuvant chemotherapy alone in patients with early-stage triple-negative breast cancer (TNBC) (Abstract LBO1-01).
Aditya Bardia, MD, MPH, of Massachusetts General Hospital Cancer Center, discusses updated phase III results from the TROPION-Breast01 study. The data showed an improvement in progression-free survival with datopotamab deruxtecan compared with investigator’s choice of chemotherapy across all subgroups of patients with inoperable or metastatic hormone receptor–positive, HER2-negative breast cancer who have received one to two prior lines of chemotherapy (Abstract GS02-01).
The ASCO Post Staff
Daniel G. Stover, MD, of The Ohio State University Comprehensive Cancer Center, discusses a biomarker analysis from the PALLAS adjuvant trial, which compared 2 years of the CDK4/6 inhibitor palbociclib with endocrine therapy vs endocrine therapy alone, as adjuvant treatment for patients with stage II–III hormone receptor–positive, HER2-negative breast cancer. The genomic subtype PAM50 was defined in the protocol of the PALLAS trial as the primary biomarker for analysis of prediction and prognosis (Abstract GS03-07).
The ASCO Post Staff
Seema Khan, MD, of Northwestern University and the Robert H. Lurie Comprehensive Cancer Center, discusses the 5-year clinical outcomes of ECOG-ACRIN 4112, a prospective trial that supports the omission of radiotherapy after surgery in patients with ductal carcinoma in situ who have a low DCIS score and its use in patients with intermediate/high DCIS scores (Abstract GS03-01).
